Skip to main content

RSV vaccine competition heats up as Pfizer’s shot for older adults gets FDA approval

Global market for RSV vaccine could reach $17 billion by 2033, analysts say.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.